Opinion of the Transparency Council – donepezilum

At its Meeting on 23 May 2022, the Transparency Council adopted Opinion No. 83/2022 on reimbursement of medicines containing the active substance donepezilum for indications for use or posology or route of administration different from those specified in the Summary of Product Characteristics, i.e. dementia with Lewy bodies; dementia in the course of Parkinson’s disease.

Publication with the minutes of the Transparency Council meeting